OBJECTIVES: We sought to define the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium. BACKGROUND: Multiple cellular events that occur during pathological remodeling of the failing ventricle are implicated in the genesis of ventricular tachycardia (VT), including interstitial fibrosis. Recent studies suggest that ventricular fibrosis is reversible, and current anti-remodeling therapies attenuate ventricular fibrosis. However, the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium is currently not well defined. METHODS: Class II histone deacetylases (HDACs) have been implicated in promoting collagen biosynthesis. As these enzymes are inhibited by protein kinase D1 (PKD1), we studied mice with cardiomyocyte-specific transgenic over-expression of a constitutively active mutant of PKD1 (caPKD). caPKD mice were compared with animals in which cardiomyopathy was induced by severe thoracic aortic banding (sTAB). Hearts were analyzed by echocardiographic and electrocardiographic means. Interstitial fibrosis was assessed by histology and quantified biochemically. Ventricular arrhythmias were induced by closed-chest, intracardiac pacing. RESULTS: Similar degrees of hypertrophic growth, systolic dysfunction and mortality were observed in the two models. In sTAB mice, robust ventricular fibrosis was readily detected, but myocardial collagen content was significantly reduced in caPKD mice. As expected, VT was readily inducible by programmed stimulation in sTAB mice and VT was less inducible in caPKD mice. Surprisingly, episodes of VT manifested longer cycle lengths and longer duration in caPKD mice. CONCLUSION: Attenuated ventricular fibrosis is associated with reduced VT inducibility, increased VT duration, and significantly longer arrhythmia cycle length.
OBJECTIVES: We sought to define the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium. BACKGROUND: Multiple cellular events that occur during pathological remodeling of the failing ventricle are implicated in the genesis of ventricular tachycardia (VT), including interstitial fibrosis. Recent studies suggest that ventricular fibrosis is reversible, and current anti-remodeling therapies attenuate ventricular fibrosis. However, the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium is currently not well defined. METHODS: Class II histone deacetylases (HDACs) have been implicated in promoting collagen biosynthesis. As these enzymes are inhibited by protein kinase D1 (PKD1), we studied mice with cardiomyocyte-specific transgenic over-expression of a constitutively active mutant of PKD1 (caPKD). caPKD mice were compared with animals in which cardiomyopathy was induced by severe thoracic aortic banding (sTAB). Hearts were analyzed by echocardiographic and electrocardiographic means. Interstitial fibrosis was assessed by histology and quantified biochemically. Ventricular arrhythmias were induced by closed-chest, intracardiac pacing. RESULTS: Similar degrees of hypertrophic growth, systolic dysfunction and mortality were observed in the two models. In sTAB mice, robust ventricular fibrosis was readily detected, but myocardial collagen content was significantly reduced in caPKD mice. As expected, VT was readily inducible by programmed stimulation in sTAB mice and VT was less inducible in caPKD mice. Surprisingly, episodes of VT manifested longer cycle lengths and longer duration in caPKD mice. CONCLUSION: Attenuated ventricular fibrosis is associated with reduced VT inducibility, increased VT duration, and significantly longer arrhythmia cycle length.
Authors: J A Hill; M Karimi; W Kutschke; R L Davisson; K Zimmerman; Z Wang; R E Kerber; R M Weiss Journal: Circulation Date: 2000-06-20 Impact factor: 29.690
Authors: Joseph A Hill; Beverly Rothermel; Ki-Dong Yoo; Barry Cabuay; Elaine Demetroulis; Robert M Weiss; William Kutschke; Rhonda Bassel-Duby; R Sanders Williams Journal: J Biol Chem Date: 2002-01-10 Impact factor: 5.157
Authors: Colin T Maguire; Hiroko Wakimoto; Vickas V Patel; Peter E Hammer; Kimberlee Gauvreau; Charles I Berul Journal: Physiol Genomics Date: 2003-09-29 Impact factor: 3.107
Authors: William B Lea; Eun Soo Kwak; James M Luther; Susan M Fowler; Zuofei Wang; Ji Ma; Agnes B Fogo; Nancy J Brown Journal: Kidney Int Date: 2009-02-18 Impact factor: 10.612
Authors: Rick B Vega; Brooke C Harrison; Eric Meadows; Charles R Roberts; Philip J Papst; Eric N Olson; Timothy A McKinsey Journal: Mol Cell Biol Date: 2004-10 Impact factor: 4.272
Authors: Shiro Nakamori; An H Bui; Jihye Jang; Hossam A El-Rewaidy; Shingo Kato; Long H Ngo; Mark E Josephson; Warren J Manning; Reza Nezafat Journal: J Magn Reson Imaging Date: 2017-07-24 Impact factor: 4.813
Authors: Ryan S Williams; James A deLemos; Vassilis Dimas; Joan Reisch; Joseph A Hill; R Haris Naseem Journal: Clin Cardiol Date: 2011-06-14 Impact factor: 2.882
Authors: Wael A AlJaroudi; Marwan M Refaat; Robert H Habib; Laila Al-Shaar; Madhurmeet Singh; Rebecca Gutmann; Heather L Bloom; Samuel C Dudley; Patrick T Ellinor; Samir F Saba; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Indrani Halder; Barry London Journal: Am J Cardiol Date: 2015-01-15 Impact factor: 2.778
Authors: Jeff M Berry; Vien Le; David Rotter; Pavan K Battiprolu; Bennett Grinsfelder; Paul Tannous; Jana S Burchfield; Michael Czubryt; Johannes Backs; Eric N Olson; Beverly A Rothermel; Joseph A Hill Journal: Circ Res Date: 2011-06-23 Impact factor: 17.367
Authors: Vassilis Dimas; Colby Ayers; James Daniels; Jose A Joglar; Joseph A Hill; R Haris Naseem Journal: Pacing Clin Electrophysiol Date: 2010-10-14 Impact factor: 1.976
Authors: Xue Liu; Yuanjian Chen; Cody W McCoy; Tieqiang Zhao; Darryl L Quarles; Min Pi; Syamal K Bhattacharya; Gwendalyn King; Yao Sun Journal: Am J Hypertens Date: 2016-08-19 Impact factor: 2.689
Authors: Domenico M Taglieri; Keven R Johnson; Brian T Burmeister; Michelle M Monasky; Matthew J Spindler; Jaime DeSantiago; Kathrin Banach; Bruce R Conklin; Graeme K Carnegie Journal: J Mol Cell Cardiol Date: 2013-10-23 Impact factor: 5.000